AstraZeneca reported two positive Phase III lung cancer readouts: SAFFRON in 338 patients with EGFR-mutated NSCLC and MET overexpression/amplification showed statistically significant, clinically meaningful gains in progression-free survival and overall survival for Tagrisso plus Orpathys versus chemotherapy, while DESTINY-Lung04 in 454 patients showed Enhertu significantly improved progression-free survival versus standard of care in first-line HER2-mutant non-squamous NSCLC. Both studies were announced as top-line results, with detailed data slated for upcoming medical meetings and regulatory submissions.

Why It Matters To Oncology

• SAFFRON addresses a common resistance pathway after EGFR TKI therapy: AstraZeneca said roughly one-third of tumors progressing on Tagrisso develop MET overexpression or amplification, a poor-prognosis subgroup with a clear biomarker-defined need.

• The company said SAFFRON is the first global Phase III trial to show both progression-free and overall survival benefit in this setting, supporting a potential all-oral, biomarker-directed option with osimertinib plus savolitinib.

• DESTINY-Lung04 adds a separate first-line signal in HER2-mutant NSCLC, where Enhertu beat platinum-pemetrexed plus pembrolizumab on progression-free survival, potentially moving the ADC earlier in care.

The Financials

• The dual wins help offset the same-day negative update for bispecific antibody volrustomig and reinforce AstraZeneca's depth in thoracic oncology.

• Orpathys is being jointly developed with HUTCHMED, while Enhertu is partnered with Daiichi Sankyo, meaning any label expansions could have shared commercial upside.

• Regulatory filings are expected after full data presentation, with potential value tied to expanding use in biomarker-selected NSCLC populations.

What They're Saying

• Susan Galbraith, AstraZeneca's EVP of oncology hematology R&D, said the Tagrisso-Orpathys combination could become the first biomarker-directed, all-oral option for this post-EGFR-TKI setting.

• SAFFRON principal investigator Shun Lu said the results highlight both the combination's potential and the urgency of MET testing to guide treatment decisions.

• Galbraith also said DESTINY-Lung04 is the first study to show progression-free survival benefit over standard care in first-line HER2-mutant NSCLC, supporting Enhertu's move into earlier treatment.

What's Next

• AstraZeneca plans to present full SAFFRON and DESTINY-Lung04 data at upcoming scientific meetings.

• The company said both readouts will be shared with global regulatory authorities.

• Key remaining questions for clinicians include magnitude of benefit, safety and tolerability in broader practice, and how biomarker testing workflows for MET and HER2 will shape uptake.